CORDIS
EU research results

CORDIS

English EN

ELDICO ED, Shaping the Future of Crystallography - The First Pure Electron Diffraction Equipment for Nano-Crystallography

Project information

Grant agreement ID: 889359

Status

Ongoing project

  • Start date

    1 December 2019

  • End date

    31 March 2020

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

ELDICO SCIENTIFIC AG

Switzerland

Objective

Crystal structure determination is still a key issue in pharmaceutical industry. Any compound requires its 3D atomic structure to become “fully characterized” for patenting and marketing approval. However, only the structure of the 10% of all crystalline substances can be determine. The reason: Conventional X-ray diffraction methods are limited because they require crystal of a minimum size of 10 x 10 μm2 and high quality to be measured, which are often time consuming or even impossible to produce. For example in drug discovery the 90% of known, but not fully characterized crystalline compounds, could be rapidly screened for their scientific or commercial potential. Although electron diffraction technique overcomes the limitations of current techniques and allows investigations on nano-crystalline systems, currently there are no commercial instruments dedicated exclusively to electron diffraction.
With ELDICO ED we bring to the market the first equipment (patent pending) designed to perform electron diffraction. We offer an electron diffractometer for the analysis of solid compounds enabling crystallographers entering the sub-µm regime for structural analysis of hitherto unmeasurable nano-crystalline particles. That way, they produce important structural information faster, with better quality and at lower cost, overcoming the limitations of X-ray analysis.
We are opening up a new market segment: Pure Electron Diffraction. Our technology will impact the pharma sector by unlocking the characterisation of the 500k existing potential new drugs in their libraries, shortening time-to-market by 10%, saving €9-18bn per annum for testing and increasing revenues of up to €310M per annum for every new drug that comes to the market. Similar impact in key sectors like research institutes, agrochemicals and Advanced Nanomaterials is expected.
With ELDICO ED we forecast generating revenues of €25.3M (ROI: 11.84) and incorporating 15 employees to our company during 2022-2024
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

ELDICO SCIENTIFIC AG

Address

Park Innovaare Delivery Lab
5234 Villigen

Switzerland

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 889359

Status

Ongoing project

  • Start date

    1 December 2019

  • End date

    31 March 2020

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

ELDICO SCIENTIFIC AG

Switzerland